Pfizer and BioNTech have enrolled the first participants in a clinical trial of a vaccine tailored to the Omicron coronavirus variant as the companies weigh whether they need to replace their existing Covid-19 jab.
The drugmakers on Tuesday said the study would evaluate the safety, tolerability, and efficacy of an Omicron-based vaccine candidate in 1,420 adults aged 18 to 55 years of age.
It is the first human trial of an Omicron-specific vaccine by a big western drugmaker and will play a pivotal role in determining whether Pfizer and BioNTech adjust a plan to manufacture 4bn doses of their existing jab in 2022.
您已閱讀21%（617字），剩余79%（2391字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。